Importantly, the HPV test approved by the FDA for screening via HPV Testing Alone is a DNA-based hrHPV
Modeling found that cotesting does not offer any benefit in terms of cancer reduction or life-years gained over hrHPV
testing alone but increases the number of tests and procedures per each cancer case averted," the Task Force members noted in the draft recommendation statement.
In the group as a whole, the most prevalent hrHPV
types, in descending order of frequency, were HPV 16, 58, 35, 52, 51 and 45.
A reasonable approach to managing a positive hrHPV
result, advises the panel, is to triage hrHPV
-positive women using a combination of genotyping for HPV 16 and 18 and reflex cytology for women positive for the 12 other hrHPV
genotypes (FIGURE 2).
Preventive Services Task Force," the authors noted, adding that hrHPV
testing was also approved for identifying specific high-risk types of HPV for triage in select settings.
HPV DNA full genotyping tests, which allow individual determination of several Alpha-PV genotypes, including all 12 officially recognized hrHPV
genotypes, are the largest group of currently available commercial HPV tests.
5) At least 21% of women in the general South African population are estimated to harbour cervical HPV infection at a given time,1 but the prevalence of hrHPV
may be as high as 60% in certain populations (unpublished data) and 85% in women infected with HIV.
Food and Drug Administration (FDA)-cleared or -approved hrHPV
test available for which the FDA granted its approval based on clinical evidence of efficacy at a five-year interval.
2,9) For women screened with cotesting, a relatively small percentage of cases have negative Pap test and positive HRHPV
DNA testing will replace cytology as primary screening test for CC, but its drawback as stand-alone CC screening test is its low specificity, causing overdiagnosis and overtreatment.
primary screening increases the incidence of colposcopy, the specificity of cytology makes it the logical reflex test to define women who require further evaluation.
testing was not indicated "in most clinical settings," mainly because of substantial concerns about the specificity of primary hrHPV
screening and the potential harms, the lack of a well-defined and evaluated strategy to manage hrHPV
-positive women, and inadequate information to define appropriate screening intervals for those who test negative, the panel wrote.